JP2018516849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516849A5 JP2018516849A5 JP2017550514A JP2017550514A JP2018516849A5 JP 2018516849 A5 JP2018516849 A5 JP 2018516849A5 JP 2017550514 A JP2017550514 A JP 2017550514A JP 2017550514 A JP2017550514 A JP 2017550514A JP 2018516849 A5 JP2018516849 A5 JP 2018516849A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 208000015122 neurodegenerative disease Diseases 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 238000003786 synthesis reaction Methods 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 229940125644 antibody drug Drugs 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007876 drug discovery Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1505239.2 | 2015-03-27 | ||
| GBGB1505239.2A GB201505239D0 (en) | 2015-03-27 | 2015-03-27 | Antibody |
| GB1600871.6A GB2541477A (en) | 2015-03-27 | 2016-01-18 | Antibody |
| GB1600871.6 | 2016-01-18 | ||
| PCT/GB2016/050804 WO2016156803A1 (en) | 2015-03-27 | 2016-03-23 | Antibody that recognises the t14 peptide of ache |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516849A JP2018516849A (ja) | 2018-06-28 |
| JP2018516849A5 true JP2018516849A5 (enExample) | 2019-04-25 |
| JP7327897B2 JP7327897B2 (ja) | 2023-08-16 |
Family
ID=53178191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550514A Active JP7327897B2 (ja) | 2015-03-27 | 2016-03-23 | Ａｃｈｅのｔ１４ペプチドを認識する抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10954306B2 (enExample) |
| EP (1) | EP3274371B1 (enExample) |
| JP (1) | JP7327897B2 (enExample) |
| KR (1) | KR102626626B1 (enExample) |
| CN (1) | CN107531796A (enExample) |
| AU (1) | AU2016240020B2 (enExample) |
| BR (1) | BR112017020769A2 (enExample) |
| CA (1) | CA2979972A1 (enExample) |
| ES (1) | ES2952723T3 (enExample) |
| GB (2) | GB201505239D0 (enExample) |
| MX (1) | MX392158B (enExample) |
| RU (1) | RU2729491C2 (enExample) |
| WO (1) | WO2016156803A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2539161A (en) * | 2014-11-26 | 2016-12-14 | Neuro-Bio Ltd | Neurodegenerative disorders |
| GB2546773B (en) * | 2016-01-28 | 2020-06-17 | Neuro Bio Ltd | Cancer |
| GB201705044D0 (en) * | 2017-03-29 | 2017-05-10 | Neuro-Bio Ltd | Biomarker |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| GB202112831D0 (en) * | 2021-09-09 | 2021-10-27 | Neuro Bio Ltd | Biomarker |
| GB202113941D0 (en) | 2021-09-29 | 2021-11-10 | Neuro Bio Ltd | Skin biomarker |
| WO2024052650A1 (en) | 2022-09-08 | 2024-03-14 | Neuro-Bio Ltd | Lateral flow device for diagnosing alzheimer's disease using the t14 peptide |
| GB202308799D0 (en) | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Neurodegenerative disease |
| GB202308779D0 (en) * | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Aptamer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606040D0 (en) * | 1996-03-22 | 1996-05-22 | Isis Innovation | Active peptide |
| US20040038875A1 (en) * | 2000-03-29 | 2004-02-26 | Greenfield Susan Adele | Alpha 7nicotinic receptor screening assays |
| GB0028578D0 (en) * | 2000-11-23 | 2001-01-10 | Synaptica Ltd | Screening assays |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
| CN101287990B (zh) * | 2005-08-16 | 2012-07-04 | 健泰科生物技术公司 | 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性 |
| GB0708646D0 (en) * | 2007-05-04 | 2007-06-13 | Enkephala Ltd | Biologically active C-terminal fragment of acetylcholinesterase |
| US8541185B2 (en) * | 2007-09-24 | 2013-09-24 | Technion Research & Development Foundation Limited | Method of predicting responsiveness to autologous adoptive cell transfer therapy |
| CN101530162B (zh) * | 2008-03-10 | 2011-11-23 | 北京大北农科技集团股份有限公司 | 一种新型蛋白饲料添加剂的制备方法 |
-
2015
- 2015-03-27 GB GBGB1505239.2A patent/GB201505239D0/en not_active Ceased
-
2016
- 2016-01-18 GB GB1600871.6A patent/GB2541477A/en not_active Withdrawn
- 2016-03-23 BR BR112017020769A patent/BR112017020769A2/pt active Search and Examination
- 2016-03-23 WO PCT/GB2016/050804 patent/WO2016156803A1/en not_active Ceased
- 2016-03-23 CN CN201680021081.0A patent/CN107531796A/zh active Pending
- 2016-03-23 RU RU2017133649A patent/RU2729491C2/ru active
- 2016-03-23 EP EP16713029.3A patent/EP3274371B1/en active Active
- 2016-03-23 AU AU2016240020A patent/AU2016240020B2/en not_active Ceased
- 2016-03-23 ES ES16713029T patent/ES2952723T3/es active Active
- 2016-03-23 KR KR1020177027589A patent/KR102626626B1/ko active Active
- 2016-03-23 JP JP2017550514A patent/JP7327897B2/ja active Active
- 2016-03-23 MX MX2017012397A patent/MX392158B/es unknown
- 2016-03-23 US US15/561,021 patent/US10954306B2/en active Active
- 2016-03-23 CA CA2979972A patent/CA2979972A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516849A5 (enExample) | ||
| US12313637B2 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43 | |
| Collins et al. | The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients | |
| Wang-Dietrich et al. | The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease | |
| Davies et al. | Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies | |
| US6680173B2 (en) | Diagnosis of tauopathies | |
| Rosen et al. | Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease | |
| RU2017133649A (ru) | Антитело, которое распознает пептид т14 асне | |
| Satoh et al. | TMEM106B expression is reduced in Alzheimer’s disease brains | |
| TWI569014B (zh) | 神經退化性疾病個體之抗體可辨識之小分子之鑑定 | |
| Wittenberg et al. | Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases | |
| US20140024053A1 (en) | Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury | |
| US20230220401A1 (en) | Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof | |
| JP5934183B2 (ja) | ミオパチーを特性化するための組成物及び方法 | |
| Wang et al. | Aβ1-42-containing platelet-derived extracellular vesicle is associated with cognitive decline in Parkinson’s disease | |
| EP2769220B1 (en) | Biomarker for autoimmune disease | |
| JP7645514B2 (ja) | 神経系細胞に由来する細胞外小胞の回収方法 | |
| CN116626294B (zh) | 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质 | |
| EP1365018A1 (en) | CD100 semaphorin in myelination | |
| US20220260593A1 (en) | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia | |
| CN120187864A (zh) | 使用t14肽诊断阿尔茨海默症的侧向流装置 | |
| CN105556306B (zh) | 用于监测多发性硬化(ms)的方法和预后试剂盒 | |
| US20230190967A1 (en) | Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent | |
| JP2023017805A (ja) | 神経学的状態検出のためのＳ１００β及びアイソフォーム | |
| Schmidt | Identification of vascular endothelial growth factor receptor 3 (VEGFR3) as an in vitro and in vivo substrate of the Alzheimer's Disease linked protease BACE2 |